Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1α induction in response to hypoxic stress and growth factors

Cancer Research

Volumn 65, Issue 11, 2005, Pages 4918-4928

  Chau, Noan Minh ^a   Rogers, Paul ^a   Aherne, Wynne ^a   Carroll, Veronica ^a   Collins, Ian ^a   McDonald, Edward ^a   Workman, Paul ^a   Ashcroft, Margaret ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE MESYLATE; GLUCOSE TRANSPORTER 1; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LUCIFERASE; SOMATOMEDIN C;

ALPHA CHAIN; ARTICLE; CANCER INVASION; CELL ASSAY; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPOXIA; METASTASIS; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INSULIN-LIKE GROWTH FACTOR I; ISOQUINOLINES; LUCIFERASES; NUCLEAR PROTEINS; OXAZINES; TRANSCRIPTION FACTORS;

EID: 19644393302     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4453     Document Type: Article

References (43)

1. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
2. Carroll V, Ashcroft M. Targeting the molecular basis for tumour hypoxia. Expert Rev Mol Med 2005;7:1-16.
3. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
4. Potter C, Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 2004;3:164-7.
5. Melillo G. HIF-1: a target for cancer, ischemia and inflammation - too good to be true? Cell Cycle 2004;3:154-5.
6. Maynard MA, Qi H, Chung J, et al. Multiple splice variants of the human HIF-3 α locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem 2003;278:11032-40.
7. Makino Y, Cao R, Svensson K, et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001;414:550-4.
8. Makino Y, Kanopka A, Wilson WJ, Tanaka H, Poellinger L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3α: locus. J Biol Chem 2002;277:32405-8.
9. 2-regulated prolyl hydroxylation. Science 2001;292:468-72.
10. 2 sensing. Science 2001;292:464-8.
11. Ebert BL, Bunn HF. Regulation of transcription by hypoxia requires a multiprotein complex that includes hypoxia-inducible factor 1, an adjacent transcription factor, and p300/CREB binding protein. Mol Cell Biol 1998;18:4089-96.
12. Arany Z, Huang LE, Eckner R, et al. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA 1996;93:12969-73.
13. Bardos JI, Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. BioEssays 2004;26:262-9.
14. Bardos JI, Ashcroft M. Negative and positive regulation of HIF-1: a complex network. Biochim Biophys Acta. In press 2005.
15. Giaccia A, Sum BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003;2:803-11.
16. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004;5:429-41.
17. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 2000;6:1335-40.
18. Kung AL, Zabludoff SD, France DS, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004;6:33-43.
19. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-75.
20. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor la and vascular endothelial growth factor formation. Mol Cancer Ther 2003;2:235-43.
21. Welsh SJ, Bellamy WT, Briehl MM, Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1α protein expression: Trx-1 over-expression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 2002;62:5089-95.
22. Yeo EJ, Chun YS, Cho YS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003;95:516-25.
23. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α. Mol Cancer Ther 2004;3:233-44.
24. Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002;62:4316-24.
25. Rapisarda A, Shoemaker RH, Melillo G. Targeting topoisomerase I to inhibit hypoxia inducible factor 1. Cell Cycle 2004;3:172-5.
26. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213-7.
27. Bardos JI, Chau NM, Ashcroft M. Growth factor-mediated induction of HDM2 positively regulates hypoxia-inducible factor 1α expression. Mol Cell Biol 2004;24:2905-14.
28. Mottet D, Dumont V, Deccache Y, et al. Regulation of hypoxia-inducible factor-1α protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3βpathway in HepG2 cells. J Biol Chem 2003;278:31277-85.
29. Berra E, Roux D, Richard DE, Pouyssegur J. Hypoxia-inducible factor-1 α (HIF-1 α) escapes O(2)-driven proteasomal degradation irrespective of its subcellular localization: nucleus or cytoplasm. EMBO Rep 2001;2:615-20.
30. Gupta RS, Krepinsky JJ, Siminovitch L. Structural determinants responsible for the biological activity of (-)-emetine, (-)-cryptopleurine, and (-)-tylocrebrine: structure-activity relationship among related compounds. Mol Pharmacol 1980;18:136-43.
31. Bhansali KG, Kook AM. Synthesis and characterisation of a series of 5H-benzo[a]phenoxazin-5-one derivatives as potential antiviral/antitumor agents. Heterocycles 1993;36:1239-51.
32. Saito H, Kobayashi S, Uosaki Y, et al. Synthesis and biological evaluation of quinocarcin derivatives. Chem Pharm Bull (Tokyo) 1990;38:1278-85.
33. Sohda M, Ishikawa H, Masuda N, et al. Pretreatment evaluation of combined HIF-1α, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer 2004;110:838-44.
34. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell bead-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;53:1192-202.
35. Ryan HE, Poloni M, McNulty W, et al. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res 2000;60:4010-5.
36. Sun X, Kanwar JR, Leung E, Lehnert K, Wang D, Krissansen GW. Gene transfer of antisense hypoxia inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther 2001;8:638-45.
37. Unruh A, Ressel A, Mohamed HG, et al. The hypoxia-inducible factor-1α is a negative factor for tumor therapy. Oncogene 2003;22:3213-20.
38. Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003;361:2235-42.
39. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 2004;64: 1475-82.
40. Hewitson KS, McNeill LA, Elkins JM, Schofield CJ. The role of iron and 2-oxoglutarate oxygenases in signalling. Biochem Soc Trans 2003;31:510-5.
41. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26.
42. Grollman AP. Inhibitors of protein biosynthesis. V. Effects of emetine on protein and nucleic acid biosynthesis in HeLa cells. J Biol Chem 1968;243:4089-94.
43. Bunnell CA, Supko JG, Eder JP Jr, et al. Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies. Cancer Chemother Pharmacol 2001;48:347-55.